CMND Stock Analysis: Buy, Sell, or Hold?
CMND - Clearmind Medicine Inc. Common Shares
$1.16
-0.54 (-31.76%)
▼
5d:
-34.09%
30d:
-33.71%
90d:
-70.85%
WAIT
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Sep 10, 2026
4d
Get Alerted When CMND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CMND is down 34.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CMND is down 34.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CMND is currently trading at $1.16, which is considered oversold relative to its 30-day fair value range of $1.55 to $1.87.
Technical Outlook: Technically, CMND is in a uptrend. The price is currently testing key support at $1.16. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 31.8% recently.
Market Sentiment: CMND scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CMND is in a uptrend. The price is currently testing key support at $1.16. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 31.8% recently.
Market Sentiment: CMND scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.55 -
$1.87
Company Quality Score
46/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
41.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (38/100)
- BEARISH: Downward momentum (-31.8%)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.55 -
$1.87
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.16
Resistance Level
$2.10
Current Trend
Uptrend
Technical data as of
Sep 4, 2026
Fundamental Context
Share & Embed Analysis
Last updated: September 04, 2026 7:13 PM ET
Data refreshes hourly during market hours. Next update: 8:13 PM
Data refreshes hourly during market hours. Next update: 8:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CMND showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 53 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 55 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 51 HOLD |
